All In Biotech

Free tool

FAERS Monitor: Tigan

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 017530 or its brand name (Tigan, Trimethobenzamide Hydrochloride). Reports on generic versions are filed under their own applications.

Reports

1,417

Serious

494

35% of reports

Hospitalization

273

Death reported

61

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • nausea332
  • somnolence228
  • dizziness166
  • vomiting132
  • yawning121
  • drug ineffective102
  • blood pressure decreased101
  • fatigue93
  • fall78
  • blood pressure increased68
  • feeling abnormal66
  • drug hypersensitivity62
  • asthenia60
  • pain58
  • dyspnoea57

Reports by year received

View as table
YearReports
200424
200528
200630
200744
200830
200927
201032
201141
201251
201334
201422
201545
201681
2017161
2018214
2019183
2020181
2021127
202231
202312
202411
20251
20267

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,742 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
yawningSignal121705.3592.280,578
blood pressure decreasedSignal10122.618.72,066
somnolenceSignal22816.814.93,407
blood pressure increasedSignal686.65.2320
nauseaSignal3326.25.71,508
dizzinessSignal1664.94.3530
drug hypersensitivitySignal624.83.7182
vomitingSignal1324.23.5322
feeling abnormalSignal664.13.2153
fallSignal783.52.8137
astheniaSignal602.41.847
fatigue931.81.532
dyspnoea571.51.29
pain581.41.16
drug ineffective1021.11.02

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.